Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

Core Insights - Sanofi, Formation Bio, and OpenAI are collaborating to create AI-powered software aimed at accelerating drug development and improving the efficiency of bringing new medicines to patients [1][2][3] - This partnership marks a pioneering collaboration in the pharmaceutical and life sciences sectors, focusing on custom solutions throughout the drug development lifecycle [1][4] Company Summaries Sanofi - Sanofi aims to become the first biopharma company powered by AI at scale, leveraging proprietary data to develop advanced AI models [2][3] - The CEO of Sanofi emphasized that this collaboration is a significant step towards transforming drug development and addressing the needs of patients awaiting innovative treatments [3][5] Formation Bio - Formation Bio is characterized as a tech-driven and AI-native pharmaceutical company, focused on enhancing drug development efficiency [6] - The company provides engineering resources and operates at the intersection of pharma and AI, aiming to accelerate all aspects of drug development and clinical trials [4][6] OpenAI - OpenAI contributes its leading AI capabilities, including model fine-tuning and deep AI expertise, to support the collaboration [3][4] - The COO of OpenAI highlighted the immense potential of AI to expedite drug development and improve patient outcomes [4][5]